2020
Molecular profiling of metastatic breast cancer (MBC) and target-based therapeutic matching in an Asian tertiary phase I oncology unit.
Walsh R, Ngoi N, Ong R, Ow S, Wong A, Eng L, Lim Y, Heong V, Sundar R, Soo R, Yong W, Chee C, Goh B, Lee S, Tan D, Lim J. Molecular profiling of metastatic breast cancer (MBC) and target-based therapeutic matching in an Asian tertiary phase I oncology unit. Journal Of Clinical Oncology 2020, 38: 3561-3561. DOI: 10.1200/jco.2020.38.15_suppl.3561.Peer-Reviewed Original ResearchMedian progression free survivalTriple negative breast cancerPhase I unitMolecular profilingEndocrine therapyNext generation sequencingBreast cancerClinical benefit rateProgression free survivalMetastatic breast cancerPhase I studyTumor molecular profilingNegative breast cancerNext generation sequencing findingsPIK3CA E542KPan-FGFR inhibitorMatched PTPIK3CA H1047RFree survivalMBC patientsMetastatic sitesI unitsFGFR pathwayTertiary centreTumor subtypes
2017
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit
Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye S, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology 2017, 30: 185-191. PMID: 29224898, DOI: 10.1016/j.clon.2017.11.011.Peer-Reviewed Original ResearchConceptsAdvanced biliary tract carcinomaPhase I clinical trialPhase I unitABC patientsAdvanced biliary tract cancerMolecular characterisation of tumoursClinical outcomes of patientsClinical benefit rateBiliary tract carcinomaBiliary tract cancerComprehensive molecular profilingPhase I trialOutcomes of patientsCharacterisation of tumoursStable diseaseI unitsAdvanced diseaseI trialBenefit rateTargeted therapyTreatment detailsTrial discontinuationExceptional respondersPTEN lossClinical outcomes